NASDAQ:PODDInsulet Stock Price, Forecast & News

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 11 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Insulet.

Insulet is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Insulet.

Insulet Co. (NASDAQ:PODD) released its quarterly earnings results on Thursday, August, 6th. The medical instruments supplier reported $0.22 EPS for the quarter, topping the Zacks' consensus estimate of ($0.01) by $0.23. The medical instruments supplier had revenue of $226.30 million for the quarter, compared to analyst estimates of $212.41 million. Insulet had a return on equity of 24.43% and a net margin of 2.20%. Insulet's revenue was up 27.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.02 earnings per share.
View Insulet's earnings history.

Insulet issued an update on its FY 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $863.694-878.458 million, compared to the consensus revenue estimate of $849.76 million.

20 analysts have issued twelve-month target prices for Insulet's shares. Their forecasts range from $165.00 to $260.00. On average, they expect Insulet's share price to reach $223.00 in the next twelve months.
View analysts' price targets for Insulet.

Media stories about PODD stock have been trending negative this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Insulet earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Insulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), DexCom (DXCM), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Varian Medical Systems (VAR) and ABIOMED (ABMD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Veeva Systems (VEEV), Adobe (ADBE), salesforce.com (CRM), Shopify (SHOP), Teladoc Health (TDOC) and Alteryx (AYX).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by many different retail and institutional investors. Top institutional shareholders include Mint Tower Capital Management B.V. (12.74%), Frontier Capital Management Co. LLC (1.29%), Victory Capital Management Inc. (0.66%), Sumitomo Mitsui Trust Holdings Inc. (0.49%), KAMES CAPITAL plc (0.48%) and Swiss National Bank (0.39%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, Eric Benjamin, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Russell Investments Group Ltd., Chartwell Investment Partners LLC, First Trust Advisors LP, GW&K Investment Management LLC, KAMES CAPITAL plc, Sumitomo Mitsui Trust Holdings Inc., and New York State Common Retirement Fund. Company insiders that have sold Insulet company stock in the last year include Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet.

PODD stock was acquired by a variety of institutional investors in the last quarter, including Mint Tower Capital Management B.V., SeaTown Holdings Pte. Ltd., Jag Capital Management LLC, Jennison Associates LLC, Frontier Capital Management Co. LLC, Granite Investment Partners LLC, Columbus Circle Investors, and State of Alaska Department of Revenue.
View insider buying and selling activity for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

Insulet has a market capitalization of $0.00 and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

The official website for Insulet is www.insulet.com.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]